Tilray is the cannabis market leader in Canada—the largest federally legal cannabis market globally—a leader in medical cannabis across Europe, maintains over 60% market share in North American hemp wellness products, and is the fourth-largest craft beer brewer in the United States. The company recently completed the acquisition of BrewDog's global assets for £33 million and is separately negotiating U.S. and Australia assets, demonstrating aggressive expansion in the premium beverage sector.
Cyborg Score Rationale
Tilray achieved record quarterly revenue of $218 million through disciplined execution across its diversified portfolio. The company demonstrates operational momentum with strategic acquisitions, profitability improvements, and expansion into premium beverage markets. However, cannabis market volatility and regulatory risks in key markets present headwinds.
Top Insights
BrewDog acquisition (March 2026) adds ~$200M annual revenue and £33M upfront investment, creating global beverage platform of ~$500M
Carlsberg partnership beginning January 2027 grants exclusive multi-year U.S. licensing rights to produce and distribute Carlsberg, 1664, and Kronenbourg brands
International medical cannabis revenue increased 36% in recent quarter with expectations for U.S. market expansion post-federal rescheduling
Operations span 20+ countries across North America, Europe, and Latin America with advanced cultivation and distribution infrastructure
Named Competitors
Medical/Adult-Use Cannabis — Canadian cannabis producer competing in medical and adult-use markets
Hemp Wellness Products — CBD and hemp-based wellness brand portfolio (owned by Tilray)
Craft Beer — Major brewer with premium craft and mainstream beer brands
Cannabis Distribution — Large-scale U.S. cannabis retailer and producer
Recent Developments
(March 2026) Completed acquisition of BrewDog global assets including UK brewing operations and 11 brewpubs for £33M
(February 2026) Entered exclusive multi-year Carlsberg Group licensing partnership for U.S. distribution beginning January 2027
(January 2026) Record Q2 FY2026 revenue of $218M with move to net cash position
(October 2025) Record Q1 FY2026 revenue of $210M with net income delivery and adjusted EBITDA of $10M
Open the full interactive Tilray Brands, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.